Increasing Drug Development Burgeoning Market Growth
The global Clostridium difficile infection treatment market was anticipated to be US$ 840 Mn in 2018, and is expected to exhibit a CAGR of 5% during the forecast period. C. difficile is a bacterium that infects colon and causes diarrhea. C. difficile commonly affects adults in hospitals, clinics and in long-term care facilities and typically occurs after the use of antibiotics.
Increase in the consumption of antibiotics and easy availability of generic antibiotics are factors expected to drive the Clostridium difficile infection treatment market growth. Manufacturers are focusing on developments in elective treatments such as immunizations and microbiome therapeutics as an effective treatment approach for Clostridium difficile infection.
For instance, Sanofi accessed the efficacy of difficile toxoid vaccine to prevent primary symptomatic C. difficile infection (CDI). Moreover, in emerging economies, outbreaks requiring antibiotic medication are also responsible for increasing incidence of Clostridium difficile infection.
Find Out More about the Report Coverage
- Merck & Co., Inc
- Baxter International Inc.
- Sanofi S.A.
- Pfizer Inc.
- Novartis AG
- Astellas Pharma
- Eli LilIy & Company
- Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.)
- Mylan N.V.
North America Dominating Clostridium difficile Treatment Market
North America is expected to be the dominant region in the Clostridium difficile infection treatment market owing to increasing prevalence of Clostridium difficile infection. Also, increase in research and development activities for developing novel therapies is aiding market growth in the region.
For instance, Eravacycline and Omadacycline were recently approved by the US Food and Drug Administration (FDA) in 2019, intended to quell gram-positive pathogens, including Clostridioides difficile (C diff) and non-tuberculosis (TB) mycobacterial infections.
North America holds significant market share in the Clostridium difficile treatment market with 31% of total revenue and is expected to grow at a CAGR of 5.5% in the forecast period.
On the other hand, Europe represents second most lucrative region in the Clostridium difficile infection treatment market and is expected to exhibit a CAGR of 5.1% in the forecast period with 28% of market share. Attributed to the presence of domestic players offering generic drugs, Asia Pacific is expected to be a significant revenue generator during the forecast period.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Key Trends Shaping Clostridium difficile Infection Treatment Market
The launch of prophylactic medicines through microbiological approach and novel antibiotics is focused towards reduction in recurrence of C. difficile infection (CDI). Existing treatment choices for CDIs are restricted to antibiotics only. Pharmaceutical organizations are currently concentrating on developing non-antibiotic options, which will provide doctors an alternative treatment choice.
Moreover, a new class of drugs such as microbiome therapeutics is being developed for Clostridium difficile infection treatment and many leading biopharmaceutical companies are actively working on it.
This development of new class of drugs would create numerous opportunities for market players and increase the competition level for innovating drugs as better treatment option. For example, Merck’s monoclonal antibody, Zinplava (bezlotoxumab), was approved by FDA, and is the first non-antibiotic option for Clostridium difficile infection.
Increasing use of antibiotics and antimicrobial drugs is increasing the incidences of Clostridium difficile infection, worldwide. Growing incidence of hospital-acquired infections further encourages the use of these high-risk antibiotics.
According to CDC study Clostridium difficile caused almost half a million infections among patients in United States in 2015. According to Point Prevalence Survey of Antimicrobial Use in acute care patients by CDC, 50% of the patients in acute care hospitals in the U.S. received more than 2 antibiotics at a time and 23% of them were receiving it for prophylaxis increasing the risk for Clostridium difficile infection.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Key Market Players Focusing on Product Diversification
The Clostridium difficile infection treatment market is characterised as a fragmented market with Merck & Co. Inc., Baxter International Inc., and Sanofi as leading market players.
These industries continue to dominate the market for Clostridium difficile infection treatment with increasing investments in research and development, product diversification, and strategic partnerships and acquisitions to enhance product portfolio and customer base.
In Sept 2018, Astellas Pharma Inc. launched Dafclir Tablets 200 mg (generic name: fidaxomicin, “ Dafclir ”) for Clostridium difficile infection treatment in Japan. Earlier in 2018, Johnson & Johnson completed the acquisition of Actelion Ltd, which enhanced the product portfolio for Clostridium difficile infection treatment. Actelion Ltd developed a drug named Cadazolid that is effective against Clostridium difficile infection.
Explore Persistence Market Research’s expertise in promulgation of the business !
The growth in the Clostridium difficile infection treatment market is mainly attributed to increasing number of patients suffering from Clostridium difficile infections and growing inclination towards novel class of therapeutics.
Strong financial position and new product development are strategies benefiting the key market players in the Clostridium difficile infection treatment market.
Companies with research and development capabilities focused on alternative therapies such as vaccines and microbiome therapeutics are expected to positively impact growth of the Clostridium difficile infection treatment market during the forecast period.
Key Segments of the Clostridium difficile Infection Treatment Market
PMR’s study on the Clostridium difficile infection treatment market offers information divided into four important segments - drug type, route of administration, distribution channel, and region.
This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
|Route of Administration||
Key Questions Answered in PMR’s Clostridium difficile infection treatment Market Report
- Which regions will continue to remain the most profitable regional markets for Clostridium difficile infection treatment market players?
- Which factors will induce a change in the demand for Clostridium difficile infection treatment during the assessment period?
- What are the different opportunities available for emerging players in the Clostridium difficile infection treatment market?
- How supply side and demand side drivers are impacting the Clostridium difficile infection treatment market?
- How will changing trends impact the Clostridium difficile infection treatment market?
- How can market players capture the low-hanging opportunities in the ;Clostridium difficile infection treatment market in developed regions?
- Which companies are leading the Clostridium ;difficile infection treatment market?
- What are the winning strategies of stakeholders in the Clostridium difficile infection treatment market to upscale their position in this landscape?